003090.KO Daewoong
- Market cap
- KRW 699B
- P/E
- 3.8x
- P/B
- 0.54x
- ROE
- 11.1%
- Dividend yield
- 1.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 003090.KO undervalued?
Graham numberThe Graham number of Daewoong cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daewoong fundamental analysis
No fundamental analysis for Daewoong yet.
Daewoong stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daewoong
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoon…
Full company profileDaewoong financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daewoong annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.02T | 1.12T | 1.23T | 1.37T | 1.36T | 1.51T | 1.70T | 1.81T | 1.94T | 2.07T | 2.13T |
| Gross Profit | 461B | 515B | 548B | 633B | 626B | 763B | 900B | 931B | 1.05T | 1.10T | 1.15T |
| Operating Income | 61.0B | 84.7B | 85.7B | 108B | 98.1B | 183B | 207B | 196B | 282B | 262B | 249B |
| EBITDA | - | 142B | 129B | 141B | 206B | 174B | 212B | 271B | 182B | 320B | 395B |
| Net Income | 19.8B | 66.3B | 29.9B | 62.4B | 98.4B | 78.8B | 103B | 153B | 57.9B | 175B | 139B |
| EPS | - | 1,534 | 692 | 1,446 | 2,368 | 1,896 | 2,467 | 3,726 | 1,416 | 4,165 | 3,301 |
| Balance Sheet | |||||||||||
| Total Assets | 1.47T | 1.55T | 1.59T | 1.67T | 1.84T | 1.93T | 2.16T | 2.36T | 2.72T | 3.23T | 3.48T |
| Total Liabilities | 603B | 610B | 628B | 642B | 721B | 777B | 879B | 922B | 1.22T | 1.46T | 1.60T |
| Shareholders' Equity | 486B | 545B | 570B | 628B | 685B | 731B | 829B | 935B | 997B | 1.18T | 1.25T |
| Cash & Short-term Investments | 106B | 135B | 95.1B | 67.5B | 197B | 125B | 190B | 162B | 192B | 256B | 268B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 18.8B | 148B | 45.4B | 139B | 145B | 133B | 149B | 206B | 162B | 258B | 203B |
| Capital Expenditure | 174B | 74.6B | 69.7B | 53.9B | 32.0B | 68.5B | 68.0B | 229B | 336B | 348B | 337B |
| Free Cash Flow | - | 44.7B | -21.7B | 70.1B | 80.3B | 17.7B | 31.5B | -23.3B | -174B | -90.4B | -134B |
| Ratios | |||||||||||
| ROE | 4.1% | 12.2% | 5.2% | 9.9% | 14.4% | 10.8% | 12.4% | 16.3% | 5.8% | 14.9% | 11.1% |
| ROA | 1.4% | 4.3% | 1.9% | 3.7% | 5.4% | 4.1% | 4.8% | 6.5% | 2.1% | 5.4% | 4.0% |
| Net Profit Margin | 2.0% | 5.9% | 2.4% | 4.6% | 7.3% | 5.2% | 6.0% | 8.4% | 3.0% | 8.5% | 6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Daewoong dividends
- Dividend yield
- 1.80%
- Forward dividend
- 200.00 KRW
- Payout ratio
- 7.2%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 12.6B | 300 | 7.2% |
| 2024 | KRW 8.19B | 200 | 14.2% |
| 2023 | KRW 8.12B | 198 | 5.3% |
| 2022 | KRW 8.91B | 214 | 8.7% |
| 2021 | KRW 7.48B | 180 | 9.5% |
| 2020 | KRW 7.64B | 184 | 7.8% |
| 2019 | KRW 7.68B | 178 | 12.3% |
| 2018 | KRW 7.68B | 178 | 25.7% |
| 2017 | KRW 7.68B | 178 | 11.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Apr 26, 2017.
Who owns Daewoong
- Insiders 38.28%
- Institutions 8.43%
- Public & others 53.30%
- Shares outstanding 42.0M
- Free float 16.6M
Daewoong company profile
- Company name
- Daewoong
- Ticker
- 003090.KO
- ISIN
- KR7003090008
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 404
- Fiscal year end
- December
- Address
- 244 Galmachi-ro, Seongnam-si, South Korea
- Phone
- 82 2 550 8800
- Website
- daewoongholdings.com
About Daewoong
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoong Co., Ltd. was founded in 1945 and is headquartered in Seongnam-si, South Korea.
Daewoong management
2- Mr. Yeong-Hwan YoonChairman and Chief Executive Officer · born 1934
- Mr. Nan-Young JeongChief Executive Officer, President and Representative Director · born 1942